Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 5/20 | 0.50 |
| ▸ | PLG | P00747 | 1/20 | 0.49 |
| ▸ | HTR5A | P47898 | 10/20 | 0.47 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 3/20 | 0.43 |
| ▸ | HTR7 | P34969 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12874632 | 0.85 | PLAU (0.46) | PLAUPLGHTR5A | |
| SCHEMBL9907335 | 0.82 | PLAU (0.55) | PLAUPLG | |
| SCHEMBL16502809 | 0.81 | HTR5A (0.53) | PLAUHTR5ASLC9A1HTR2BHTR7 | |
| SCHEMBL9907911 | 0.81 | HTR5A (0.60) | PLAUHTR5ASLC9A1HTR2BHTR7 | |
| SCHEMBL9907943 | 0.81 | HTR5A (0.69) | PLAUHTR5ASLC9A1HTR2BHTR7 | |
| SCHEMBL9909261 | 0.80 | HTR5A (0.49) | PLAUHTR5ASLC9A1HTR2BHTR7 | |
| SCHEMBL9907915 | 0.80 | HTR5A (0.49) | PLAUHTR5ASLC9A1HTR2BHTR7 | |
| SCHEMBL9907784 | 0.79 | HTR5A (0.65) | PLAUHTR5ASLC9A1 | |
| SCHEMBL9907913 | 0.79 | HTR5A (0.55) | PLAUHTR5ASLC9A1HTR2BHTR7 | |
| Hydrochloric Acid SCHEMBL9105803 | 0.78 | HTR5A (0.64) | PLAUHTR5AHTR2BHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | PLAU 3322/4885PLG 3328/4885HTR5A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.